(SPRO) Spero Therapeutics - Ratings and Ratios

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative treatments for multi-drug resistant bacterial infections and rare diseases. With a pipeline of promising product candidates, the company is poised to address significant unmet medical needs in the US market. Its lead candidate, Tebipenem HBr, is an oral carbapenem-class antibiotic in Phase 3 development for complicated urinary tract infections, including pyelonephritis in adult patients.

The companys product portfolio also includes SPR720, a novel first-line treatment for nontuberculous mycobacterial pulmonary disease, and SPR206, which is being developed in partnership with Everest Medicines for the Greater China, South Korea, and Southeast Asian markets. Speros strategic partnerships, including its license agreement with Meiji Seika Pharma Co., Ltd. for Tebipenem HBr and with Vertex Pharmaceuticals Incorporated for SPR720, underscore its commitment to advancing its pipeline and bringing new treatments to market.

From a technical analysis perspective, Spero Therapeutics stock has shown a relatively stable trading pattern, with its 20-day simple moving average (SMA) at $0.66 and 50-day SMA at $0.70. The stocks current price of $0.68 is near its 52-week low of $0.56, suggesting potential for a rebound. The average true range (ATR) of 9.12% indicates moderate volatility, and a break above the 50-day SMA could signal a bullish trend.

Fundamentally, Spero Therapeutics has a market capitalization of $36.40M USD, with no price-to-earnings ratio due to its current loss-making status. The companys return on equity is -123.50%, reflecting the significant investment in its pipeline. However, as the company advances its product candidates through clinical trials, a successful outcome could lead to a significant increase in valuation. Based on the current technical and fundamental data, a forecast for Spero Therapeutics could be a potential price target of $1.20-$1.50 in the next 6-12 months, driven by positive clinical trial results and strategic partnerships. This represents a potential upside of 76%-121% from current levels.